JEFFREY L. EDWARDS - Corporate Board Profile

BIO-RAD LABORATORIES, INC.

Filing Date	Source Excerpt
2017-03-30	Mr. Edwards currently serves on the Board of Directors and as Audit Committee chairman of both FibroGen, Inc., a publicly traded biopharmaceutical company and Viamet Pharmaceuticals Holdings, LLC, a privately-owned biopharmaceutical company. Mr. Edwards has over 25 years of public company experience.
2018-05-04	Jeffrey L. Edwards Age: 57 Mr. Edwards retired from Allergan, Inc.... We believe that Mr. Edwards’ deep financial, capital allocation, and business development experience give him the qualifications and skills to serve as a director. Director Compensation ...Jeffrey L. Edwards received non-employee Director compensation starting in April 2017. Our Board of Directors has an Audit Committee, a Compensation Committee and a Legal and Regulatory Compliance Committee. Current Director Audit Committee Compensation Committee Legal & Regulatory Compliance Committee Jeffrey L. Edwards ✔ ✔* ✔ * Chair Between January 1, 2017 and April 25, 2017, non-employee Directors who did not serve on the Audit Committee received a cash payment of $7,083 per month, non-employee Directors who served on the Audit Committee received a cash payment of $7,917 per month, and the Audit Committee Chairman received $8,750 per month. The following table provides information about Director compensation during 2017 for our non-employee Directors. Name Fees Earned or Paid in Cash ($) Total ($) Jeffrey L. Edwards 105,000 105,000
2019-04-04	Jeffrey L. Edwards Former EVP, Chief Financial Officer of Allergan, Inc. Director Since: 2017 Age: 58 Class of Common Stock to Elect: Class B Mr. Edwards retired from Allergan, Inc., a multi-specialty health care company, in February 2015 after nearly 22 years at Allergan. From September 2005 to August 2014, he served as Executive Vice President, Finance and Business Development, Chief Financial Officer at Allergan. From 2003 to 2005 he served as Allergan’s Corporate Vice President, Corporate Development and previously served as Senior Vice President, Treasury, Tax and Investor Relations. Prior to joining Allergan, Mr. Edwards was with Banque Paribas from 1992-1993 and Security Pacific National Bank from 1983-1992, where he held various senior-level positions in the credit and business development functions. Mr. Edwards currently serves on the Board of Directors and as Audit Committee chairman of FibroGen, Inc., a publicly traded biopharmaceutical company, and on the Board of Directors and the Compensation Committee of Clearside Biomedical, Inc., a publicly traded development stage pharmaceutical company. Mr. Edwards has over 25 years of public company experience. We believe that Mr. Edwards’ deep financial, capital allocation, and business development experience give him the qualifications and skills to serve as a director. Director Compensation Our Board of Directors approved the current compensation policy for our non-employee Directors on April 25, 2017, providing for the payment of cash fees as follows: Board Role Cash Fees ($) Board Member 120,000 Lead Independent Director 15,000 Audit Committee Chair 20,000 Audit Committee Member 10,000 Legal & Regulatory Compliance Committee Chair 10,000 Legal & Regulatory Compliance Committee Member 5,000 Compensation Committee Chair 5,000 Compensation Committee Member 3,000 Jeffrey L. Edwards 140,000 COMMITTEES OF THE BOARD OF DIRECTORS Current Director Audit Committee Compensation Committee Legal & Regulatory Compliance Committee Jeffrey L. Edwards ✔ ✔* ✔ Chair Compensation Committee Member * Audit Committee Chair * Legal & Regulatory Compliance Committee Member
2020-04-01	Mr. Edwards retired from Allergan, Inc., a multi-specialty health care company, in February 2015 after nearly 22 years at Allergan. From September 2005 to August 2014, he served as Executive Vice President, Finance and Business Development, Chief Financial Officer at Allergan. ... Mr. Edwards currently serves on the Board of Directors and as Audit Committee Chair of FibroGen, Inc., a publicly traded biopharmaceutical company, and on the Board of Directors, the Compensation Committee and the Audit Committee of Clearside Biomedical, Inc., a publicly traded development stage pharmaceutical company. ... Our Board of Directors has an Audit Committee, a Compensation Committee and a Legal and Regulatory Compliance Committee. ... Jeffrey L. Edwards ... Audit Committee Member, Compensation Committee Member, Legal & Regulatory Compliance Committee Member ... Our Board of Directors approved the compensation policy that was in effect during the year ended December 31, 2019 for our non-employee Directors on April 26, 2017, providing for the payment of cash fees as follows: Board Member $120,000, Audit Committee Chair $20,000, Audit Committee Member $10,000, Compensation Committee Chair $5,000, Compensation Committee Member $3,000, Legal & Regulatory Compliance Committee Chair $10,000, Legal & Regulatory Compliance Committee Member $5,000. ... The following table provides information about Director compensation during 2019 for our non-employee Directors. Jeffrey L. Edwards Fees Earned or Paid in Cash $140,000.
2021-03-31	Jeffrey L. Edwards Former EVP, Chief Financial Officer of Allergan, Inc. Director Since: 2017 Age: 60 Class of Common Stock to Elect: Class B ...Mr. Edwards currently serves on the Board of Directors and as Audit Committee chair of FibroGen, Inc.... Director Compensation ...The following table provides information about director compensation during 2020 for our non-employee directors. Name: Jeffrey L. Edwards Fees Earned or Paid in Cash ($): 145,000 Total ($): 145,000 Committees of the Board of Directors ...Jeffrey L. Edwards Audit Committee: ✔ Compensation Committee: ✔* Legal & Regulatory Compliance Committee: ✔ *Chair
2022-03-30	Jeffrey L. Edwards, 61, Director Since: 2017, Former EVP, Chief Financial Officer of Allergan, Inc. Committees: Audit Committee (Chair), Compensation Committee, Legal & Regulatory Compliance Committee. Compensation: $145,000 in fees earned or paid in cash in 2021.
2023-03-29	Jeffrey L. Edwards Former EVP, Chief Financial Officer of Allergan, Inc. Director Since: 2017 Age: 62 Mr. Edwards retired from Allergan, Inc., a multi-specialty health care company, in February 2015 after nearly 22 years at Allergan. From September 2005 to August 2014, he served as Executive Vice President, Finance and Business Development, Chief Financial Officer at Allergan. ... Mr. Edwards currently serves on the Board of Directors and as Audit Committee chair of FibroGen, Inc., ... We believe that Mr. Edwards’ deep financial, capital allocation, and business development experience give him the qualifications and skills to serve as a director. Director Compensation Jeffrey L. Edwards Fees Earned or Paid in Cash ($): 150,000 Total ($): 150,000 Committees Audit Committee (Chair) Compensation Committee Member Legal & Regulatory Compliance Committee Member
2024-03-27	Jeffrey L. Edwards Former EVP, Chief Financial Officer of Allergan, Inc. Director Since: 2017 Age: 63 Mr. Edwards retired from Allergan, Inc., a multi-specialty health care company, in February 2015 after nearly 22 years at Allergan. From September 2005 to August 2014, he served as Executive Vice President, Finance and Business Development, Chief Financial Officer at Allergan. From 2003 to 2005 he served as Allergan’s Corporate Vice President, Corporate Development and previously served as Senior Vice President, Treasury, Tax and Investor Relations. Prior to joining Allergan, Mr. Edwards was with Banque Paribas and Security Pacific National Bank, where he held various senior-level positions in the credit and business development functions. Mr. Edwards currently serves on the Board of Directors and as Audit Committee chair of FibroGen, Inc., a publicly traded biopharmaceutical company; on the Board of Directors, the Nominating and Corporate Governance Committee and the Audit Committee of Clearside Biomedical, Inc., a publicly traded development stage pharmaceutical company; and on the Board of Directors, on the Nominating and Governance Committee and as the Audit Committee Chair of Lifecore Biomedical, Inc., a publicly traded company which is a fully integrated Contract Development and Manufacturing Organization (CDMO) within the medical device and pharmaceuticals sectors. Mr. Edwards has over 30 years of public company experience. We believe that Mr. Edwards’ deep financial, capital allocation, and business development experience give him the qualifications and skills to serve as a director. Director Compensation Our Human Resources Department periodically provides the Chairman of the Board with market information on, and trends regarding, non-employee director compensation from other companies including our peer group (our method of determining our peer group is described in the section titled “Our Process for Setting Executive Compensation” below). The Chairman of the Board then will recommend any changes in non-employee director compensation to the Board, and the Board will either approve or not approve such recommended changes. Employee directors receive no additional compensation for Board service. On December 6, 2019, our Board of Directors approved the compensation policy that was in effect until September 30, 2023 for our non-employee directors, providing for the payment of cash fees as follows: Board Role Cash Fees (until September 30, 2023) ($) Board Member 125,000 Lead Independent Director 15,000 Audit Committee Chair 20,000 Audit Committee Member 10,000 Legal & Regulatory Compliance Committee Chair 10,000 Legal & Regulatory Compliance Committee Member 5,000 Compensation Committee Chair 5,000 Compensation Committee Member 3,000 On October 20, 2023, our Board of Directors approved a new compensation policy, effective October 1, 2023, providing for payment of fees for our non-employee directors as follows: Board Role Cash Fees (effective October 1, 2023) ($) Board Member 300,000* Lead Independent Director 25,000 Audit Committee Chair 25,000 Audit Committee Member 10,000 Legal & Regulatory Compliance Committee Chair 10,000 Legal & Regulatory Compliance Committee Member 5,000 Compensation Committee Chair 10,000 Compensation Committee Member 3,000 The following table provides information about director compensation during 2023 for our non-employee directors. Norman Schwartz serves as our Chief Executive Officer and his compensation is disclosed in the “Summary Compensation Table” beginning on page 36 of this Proxy Statement. Allison Schwartz serves as an employee and her compensation is disclosed under “Transactions with Related Persons” beginning on page 16 of this Proxy Statement. Name Fees Earned or Paid in Cash ($) Total ($) Jeffrey L. Edwards 190,000 190,000
2025-03-26	Former EVP, Chief Financial Officer of Allergan, Inc.